WFRF:(Pålhagen Sven E)
Sökning: WFRF:(Pålhagen Sven E) > (2001-2004) > Rufinamide :
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 03356naa a2200397 4500 | |
| 001 | oai:DiVA.org:liu-47472 | |
| 003 | SwePub | |
| 008 | 091011s2001 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-474722 URI |
| 024 | 7 | a https://doi.org/10.1016/S0920-1211(00)00185-62 DOI |
| 040 | a (SwePub)liu | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Pålhagen, Svenu Linköpings universitet,Hälsouniversitetet,Geriatrik4 aut0 (Swepub:liu)svepa72 |
| 245 | 1 0 | a Rufinamide :b A double-blind, placebo-controlled proof of principle trial in patients with epilepsy |
| 264 | 1 | c 2001 |
| 338 | a print2 rdacarrier | |
| 520 | a Objective: This was the first proof of principle clinical trial assessing the efficacy and safety of rufinamide as adjunctive therapy in epileptic patients. The pharmacokinetic (PK) profile of rufinamide was also determined. Methods: Fifty patients with diagnoses of partial or primary generalized tonic-clonic seizures were enrolled in this 28-day double-blind, placebo-controlled, weekly rising dose (400-1600 mg/day) trial. PK profiles were obtained after administration of single-dose rufinamide prior to and after the Double-blind phase. Results: In the evaluable patient population, seizure frequency decreased by 41% in the rufinamide group and increased by 52% in the placebo group (P = 0.040). Thirty-nine percent (39%) of rufinamide-treated and 16% of placebo-treated patients experienced reduction in seizure frequency of at least 50% relative to baseline (P = 0.096). Safety: Treatment-emergent adverse events (AEs) consisted mainly of neurologic signs and symptoms commonly associated with antiepileptic drugs (AEDs). Pharmacokinetics: At steady state, rufinamide reached a peak plasma concentration with a mean time (Tmax) of 3.4 h and a mean half-life (t1/2) of 7.3 h. No autoinduction of rufinamide metabolism occurred. Rufinamide did not influence the plasma concentration of carbamazepine, phenytoin or valproate when added to these single AED regimens. Conclusion: Rufinamide has been shown, in this proof of principle trial, to be safe and effective in reducing seizure frequency in epileptic patients with no relevant influence on the metabolism of other AEDs. © 2001 Elsevier Science B.V. | |
| 653 | a AED | |
| 653 | a Antiepileptic agents | |
| 653 | a Pharmacokinetics | |
| 653 | a Rufinamide | |
| 653 | a Seizures | |
| 653 | a MEDICINE | |
| 653 | a MEDICIN | |
| 700 | 1 | a Canger, R.u Centro Per l'Epilessia, Ospedale S. Paolo, Milan, Italy4 aut |
| 700 | 1 | a Henriksen, O.u National Centre for Epilepsy, Postbox 900, N-1337 Sandvika, Norway4 aut |
| 700 | 1 | a Van, Parys J.A.u Van Parys, J.A., Instituut Voor Epilepsie Bestrijding, Heemstede, Netherlands4 aut |
| 700 | 1 | a Riviere, M.-E.u Rivière, M.-E., CRD, S-27.7.061, Novartis Pharma AG, CH-4002 Basel, Switzerland4 aut |
| 700 | 1 | a Karolchyk, M.A.u CRD, S-27.7.061, Novartis Pharma AG, CH-4002 Basel, Switzerland4 aut |
| 710 | 2 | a Linköpings universitetb Hälsouniversitetet4 org |
| 773 | 0 | t Epilepsy Researchg 43:2, s. 115-124q 43:2<115-124x 0920-1211x 1872-6844 |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-47472 |
| 856 | 4 8 | u https://doi.org/10.1016/S0920-1211(00)00185-6 |
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Pålhagen, Sven
- Canger, R.
- Henriksen, O.
- Van, Parys J.A.
- Riviere, M.-E.
- Karolchyk, M.A.
- Artiklar i publikationen
- Epilepsy Researc ...
- Av lärosätet
- Linköpings universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
